Xencor Inc. (NASDAQ:XNCR) shares were down 3.7% during trading on Thursday . The company traded as low as $18.15 and last traded at $18.15, with a volume of 113,722 shares traded. The stock had previously closed at $18.84.

A number of research analysts have issued reports on XNCR shares. Zacks Investment Research upgraded Xencor from a “hold” rating to a “buy” rating and set a $21.00 target price on the stock in a research report on Tuesday. Canaccord Genuity reiterated a “buy” rating on shares of Xencor in a report on Tuesday, May 3rd. TheStreet upgraded Xencor from a “sell” rating to a “hold” rating in a report on Monday, April 25th. Oppenheimer Holdings Inc. reiterated a “buy” rating on shares of Xencor in a report on Monday, May 2nd. Finally, Leerink Swann reiterated an “outperform” rating and issued a $18.00 target price on shares of Xencor in a report on Wednesday, June 29th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Xencor has a consensus rating of “Buy” and an average price target of $23.29.

The stock’s market capitalization is $758.67 million. The company’s 50 day moving average is $15.04 and its 200-day moving average is $13.11.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings data on Monday, May 2nd. The biopharmaceutical company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.11. The firm had revenue of $7.30 million for the quarter, compared to the consensus estimate of $3.50 million. Analysts expect that Xencor Inc. will post ($0.78) EPS for the current year.

In related news, CEO Bassil I. Dahiyat sold 45,886 shares of the stock in a transaction dated Tuesday, May 24th. The stock was sold at an average price of $13.00, for a total transaction of $596,518.00. Following the completion of the sale, the chief executive officer now directly owns 358,186 shares in the company, valued at approximately $4,656,418. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. Its segment is related to the development of pharmaceutical products. It uses its XmAb technology platform to create antibody product candidates designed to treat autoimmune and allergic diseases, cancer and other conditions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.